Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy.

Álvaro MenaPurificación CidCarlos DueñasMaría Ángeles GarcinuñoJuan Francisco LorenzoLuis MargusinoMarina QuiñonesCarmen GrandeIria Rodríguez-OsorioÁngeles Castro

Published in: HIV clinical trials (2019)

Switching from DRV/r to DRV/c in patients under mono or dual therapy is safe and effective.

Keyphrases

hiv infected patients
antiretroviral therapy
end stage renal disease
ejection fraction
newly diagnosed
randomized controlled trial
chronic kidney disease
systematic review
prognostic factors
peritoneal dialysis
stem cells
patient reported outcomes
bone marrow
cell therapy